science translational medicine介绍
常用医学专业期刊的中英文名称
常用医学专业期刊的中英文名称1. BMJ（British Medical Journal）英国医学杂志2. JAMA（Journal of the American Medical Association）美国医学会杂志3. NEJM（New England Journal of Medicine）新英格兰医学杂志4. The Lancet柳叶刀5. Nature Medicine自然医学6. Cell医学7. Science Translational Medicine科学翻译医学8. PLOS Medicine公共科学图书馆医学9. Clinical Cancer Research临床肿瘤学研究10. Journal of Clinical Oncology临床肿瘤学杂志11. The Lancet Oncology柳叶刀肿瘤学12. Cancer Cell癌细胞13. Cancer Research癌症研究14. Gut肠道15. Journal of Hepatology肝病学杂志16. The American Journal of Gastroenterology美国胃肠病学杂志17. Circulation循环研究18. European Heart Journal欧洲心脏病学杂志19. The Journal of Clinical Investigation临床调查杂志20. Diabetes糖尿病杂志以上是一些常用的具有国际影响力的医学专业期刊的中英文名称。
这些期刊在医学领域内被广泛引用，发表的论文涵盖了各个医学领域的相关研究。
熟悉这些期刊的名称和特点对于从事医学研究的学者和医务人员来说至关重要，因为这有助于他们及时了解最新的科学进展、研究成果和临床实践指南。
同时，这些期刊也为其他相关学科的研究者提供了宝贵的参考和引用资源。
这些期刊以其严谨的学术标准和高质量的论文而闻名，多数都拥有德高望重的国际编辑委员会，并通过同行评审机制确保所发表的研究具有科学性和可靠性。
journal of translational medicine的参考文献要求
journal of translational medicine的参考文献要求参考文献是学术论文中必不可少的一部分，它提供了对已有研究进行支持、验证和引用的依据。
对于期刊《Journal of Translational Medicine》而言，合适的参考文献是非常重要的。
本文将介绍一些常见的参考文献类型，并提供相关的参考内容作为范例。
1. 学术期刊论文（Journal Articles）学术期刊论文是科学研究中最常见的参考文献类型。
对于Translational Medicine领域的论文，可以引用该领域相关的期刊，如Nature Communications、Cell Reports或者Science Translational Medicine。
以下是一些常见的参考内容范例：- A. J. Smith et al., "The role of microRNAs in translational medicine," Nature Communications, vol. 10, no. 1, p. 4252, 2019.- B. Q. Li et al., "Translational medicine approaches to diagnose, treat and prevent asthma," Cell Reports, vol. 31, no. 4, p. 107684, 2020.- C. R. Johnson et al., "Advances in gene therapy for translational medicine," Science Translational Medicine, vol. 12, no. 559, p. eaax8708, 2020.2. 综述文章（Review Articles）综述文章汇总了某一领域的研究成果，并对这些成果进行综合评述和分析。
生物学中的转化医学研究
生物学中的转化医学研究近年来，随着科技的不断发展，生物医学领域中的转化医学研究逐渐成为研究的热点之一。
生物学的本质是通过研究生物体结构、功能、特性、进化等多方面的信息，去理解生命现象。
而转化医学是将生物学研究的成果应用到治疗疾病上。
因此，转化医学是生物学的一个重要应用方向。
一、什么是转化医学？转化医学（Translational medicine）是一种将基础研究转化为临床应用和公共卫生行动的跨学科合作领域。
它综合运用多学科知识和技术，将在分子、细胞和动物层面获得的知识以及在临床实践中发现的关键问题互相交融，以期尽早推进新技术、新药物及疫苗的研究成果转化到临床实践中，最终为患者的治疗带来可持续的改进。
二、转化医学的重要性转化医学对于人类健康和长寿具有非常重要的作用。
它将实验室科学研究成果与临床实践结合起来，可以有效地加速科学研究的进展和药物的发展，提高治疗的精准度和有效性，并为解决社会和全球性的健康问题提供新的理念和应对策略。
相应地，转化医学也成为了各国医学研究的热点和共同关注的焦点。
三、转化医学中的主要技术1. 基因工程技术基因工程技术是转化医学研究领域中最为关键的技术之一。
基因工程技术不仅可用于基因修复，在癌细胞中引入外来基因编码特定的抗体，还可以用于开发自主免疫治疗方式，如CRISPR基因编辑技术，利用Cas9酶通过选择性编译、修复和复制等操作来修补、治疗基因病。
2. 细胞治疗技术细胞治疗技术是转化医学领域中的另一个重要技术。
它包括干细胞治疗、细胞免疫治疗，以及采用T细胞增殖技术和培养生产具有特定生物学特性的重组蛋白等技术等。
人们利用这些技术，可以从人体内抽取某些细胞进行培养，经过改造后再重新注射到人体内以达到治疗效果。
3. 生物芯片技术生物芯片技术是在生物体系中使用微型加工技术制造微结构芯片，利用加工、微电子、光机电各领域的技术，来实现对生物大分子和细胞等的测量、分析、检测以及细胞因子筛选和抗体筛选。
转化医学：年轻的骨髓捐献者也可能传递致病突变
一项新的测序研究表明，即使是年轻的骨髓供体也可能带有致病性突变，这些突变会在那些接受干细胞移植的急性髓系白血病（AML）或其他血液癌症患者中生根。
人们早就认识到，有少数个体看起来很健康，但血液或骨髓可能存在与血液系统恶性肿瘤相关的突变。
这种现象被称为意义不明的克隆性造血（CHIP），在健康老年个体中很常见，并且与血液肿瘤的风险增加有关。
然而，一项新的测序研究表明，即使是年轻的骨髓供体也可能带有致病性突变，这些突变会在那些接受干细胞移植的急性髓系白血病（AML）或其他血液癌症患者中生根。
这项成果于1月15日发表在《Science Translational Medicine》杂志上。
华盛顿大学医学院的儿科助理教授Sima Bhatt称：“移植医生通常倾向于寻找年轻的捐献者，因为我们认为这将减少并发症。
不过，我们有证据表明，即使是年轻健康的捐献者也可能带有突变，这将对我们的患者产生影响。
”在这项研究中，Bhatt及其同事采用了一种错误纠正的深度测序（ECS）方法，该方法旨在检测频率低至0.0001的突变。
他们以25对匹配的骨髓供体和受体为对象（没有亲属关系），对125个血液和骨髓样本开展深度测序。
他们在11名供体（44%）中发现了体细胞突变，这些供体的年龄在20至58岁。
在突变的克隆中，绝大多数的突变（84.2%）被认为致病的。
随后，所有这些风险突变都出现在干细胞移植受体的相应骨髓样本中。
通讯作者、华盛顿大学医学院的儿科副教授Todd Druley表示：“我们没想到这些多年轻、健康的捐献者也带有这种类型的突变。
我们也没有想到100%的有害突变植入到受体内。
这些结果令人震惊。
”科学家早就意识到，在干细胞移植中使用带突变的骨髓可能引起严重的并发症。
研究人员解释说，捐献骨髓中稀有的体细胞突变也会在免疫抑制的受体中迅速复制并扩增，不过人们还没有仔细鉴定过50岁以下个体的骨髓样本中的体细胞突变程度。
为了研究干细胞移植过程中传递的骨髓突变，研究人员此次利用错误校正测序评估了125个血液或骨髓样本，重点放在25例AML患者接受骨髓移植100天和一年后收集的样本以及在移植时从供体中采集的匹配样本。
转化医学(英文)
！~医药科学专业解释：转化医学；转化医学就是希望将生物医学研究的关注点放在如何将实验室的研究发现转化导向为有利病人诊断、治疗方法的提高上。
2：网络释义：a--转化或转换医学（Translational Medicine）是近两三年来国际医学健康领域出现的新概念。
b--转译医学(Translational Medicine)c--转换医学（Translational Medicine），又叫转化医学是本世纪从循证医学发展而形成的一个医学实践和干预性流行病学的理念，它融汇基础科学、社会科学、政治科学于一体...d--阿斯利康中国创新中心(ICC)初期将着重进行癌症领域临床前到临床医学之间转化医学(translational medicine)的研究。
广义上讲，转化医学(转化科学)就是使病人直接受益的对基础科学研究的应用。
Open accessAll articles published by Journal of Translational Medicine are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here.Authors of articles published in Journal of Translational Medicine are the copyright holders of their articles and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate the article, according to the BioMed Central copyright and license agreement.Article-processing chargesOpen access publishing is not without costs. Journal of Translational Medicine therefore levies an article-processing charge of £1250/$2005/€1560 for each article accepted for publication. We routinely waive charges for authors from low-income countries. Generally, if the submitting author's institution is a Member the cost of the article-processing charge is covered by the membership, and no further charge is payable. In the case of authors whose institutions are Supporter Members, however, a discounted article-processing charge is payable by the author. For further details, see our article-processing charge page. A limited number of waivers for article-processing charges are also available at the editors' discretion, and authors wishing to apply for these waivers should contact the editors.Indexing servicesFollowing publication in Journal of Translational Medicine, the full-text of each article is deposited immediately and permanently archived in PubMed Central, the US National Library of Medicine's full-text repository of life science literature, and also in repositories in e-Depot, the National Library of the Netherlands' digital archive of electronic publications. Journal of Translational Medicine is included in PubMed and all major bibliographic databases. A complete list of indexing web services that include BioMed Central's journals can be found here.Journal of Translational Medicine is tracked by Thomson Reuters (ISI)and has an Impact Factor of 3.47.Publication and peer review processAuthors will be able to check the progress of their manuscript through the submission system at any time by logging into My Journal of Translational Medicine, a personalized section of the site.Portability of peer reviewIn order to support efficient and thorough peer review, we aim to reduce the number of times a manuscript is re-reviewed after rejection from Journal of Translational Medicine, thereby speeding up the publication process and reducing the burden on peer reviewers. Therefore, please note that, if a manuscript is not accepted for publication in Journal of Translational Medicine and the authors choose to submit a revised version to another BioMed Central journal, we will pass the reviews on to the other journal's editors at the authors' request. We will reveal the reviewers' names to the handling editor for editorial purposes unless reviewers let us know when they return their report that they do not wish us to share their report with another BioMed Central journal.ReprintsHigh-quality, bound reprints can be purchased for all articles published. Please see our reprints website for further information about ordering reprints.SupplementsJournal of Translational Medicine will consider supplements based on proceedings (full articles or meeting abstracts), reviews or research. All articles submitted for publication in supplements are subject to peer review. Published supplements are fully searchable and freely accessible online and can also be produced in print. All full length articles (proceedings, reviews or research articles) are indexed by PubMed. PubMed displays the title of the supplement only in the case of meeting abstract collections. For further information, please contact us.Editorial policiesAny manuscript, or substantial parts of it, submitted to the journal must not be under consideration by any other journal. In general, the manuscript should not have already been published in any journal or other citable form, although it may have been deposited on a preprint server. Information on duplicate/overlapping publications can be found here. Authors are required to ensure that no material submitted as part of a manuscript infringes existing copyrights, or the rights of a third party.Correspondence concerning articles published in Journal of Translational Medicine is encouraged. A 'post a comment' feature is available on all articles published by Journal of Translational Medicine. Comments will be moderated by the editorial office (see our Comment policy for further information) and linked to the full-text version of the article, if suitable.Editorial standardsBioMed Central is a member of the Committee on Publication Ethics (COPE) and endorses the World Association of Medical Editors (WAME) Policy Statement on Geopolitical Intrusion on Editorial Decisions.Ethical guidelinesSubmission of a manuscript to Journal of Translational Medicine implies that all authors have read and agreed to its content, and that any experimental research that is reported in the manuscript has been performed with the approval of an appropriate ethics committee. Research carried out on humans must be in compliance with the Helsinki Declaration, and any experimental research on animals must follow internationally recognized guidelines. A statement to this effect must appear in the Methods section of the manuscript, including the name of the body which gave approval, with a reference number where appropriate. Informed consent must also be documented. Manuscripts may be rejected if the editorial office considers that the research has not been carried out within an ethical framework, e.g. if the severity of the experimental procedure is not justified by the value of the knowledge gained.For all articles that include information or clinical photographs relating to individual patients, written and signed consent from each patient to publish must also be made available if requested by the editorial staff.Journal of Translational Medicine's publisher, BioMed Central, has a legal responsibility to ensure that its journals do not publish material that infringes copyright, or that includes libellous or defamatory content. If, on review, your manuscript is perceived to contain potentially libellous content the journal Editors, with assistance from the publisher if required, will work with authors to ensure an appropriate outcome is reached.The involvement of scientific (medical) writers or anyone else who assisted with the preparation of the manuscript content should be acknowledged, along with their source of funding, as described in the European Medical Writers Association (EMWA) guidelines on the role of medical writers in developing peer-reviewed publications. If medical writers are not listed among the authors, their role should be acknowledged explicitly.Standards of reportingJournal of Translational Medicine supports initiatives aimed at improving the reporting of biomedical research. We recommend authors refer to the EQUATOR network website for further information on the available reporting guidelines for health research, and the MIBBI Portal for prescriptive checklists for reporting biological and biomedical research where applicable. Authors are requested to make use of these when drafting their manuscript and peer reviewers will also be asked to refer to these checklists when evaluating these studies. Checklists are available for a number of study designs, including randomized controlled trials (CONSORT), systematic reviews (PRISMA), observational studies (STROBE), meta-analyses of observational studies (MOOSE), diagnostic accuracy studies (STARD) and qualitative studies (RATS). For authors of systematic reviews, an additional file, linked from the Methods section, should reproduce all details concerning the search strategy. For an example of how a search strategy should be presented, see the Cochrane Reviewers' Handbook.Standardised gene nomenclature should be used throughout. Human gene symbols and names can be found in the HUGO Gene Nomenclature Committee (HGNC) database and any enquiries, or requests for new gene symbols, should be directed via email to hgnc@. Nomenclature committees for other species are listed at /about/faq#otherspecies. For mutation nomenclature please use the guidelines suggested by the Human Genome Variation Society.Authors from pharmaceutical companies, or other commercial organizations that sponsor clinical trials, should adhere to the Good Publication Practice guidelines for pharmaceutical companies, which are designed to ensure that publications are produced in a responsible and ethical manner. The guidelines also apply to any companies or individuals that work on industry-sponsored publications, such as freelance writers, contract research organizations and communications companies.Journal of Translational Medicine also supports initiatives to improve the performance and reporting of trials, part of which includes prospective registering and numbering of clinical trials. The International Committee of Medical Journal Editors (ICMJE) has implemented the World Health Organisation (WHO) definition of clinical trials which states that a clinical trial is any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes. This definition includes phase I to Phase IV trials.Authors of protocols or reports of such clinical trials, where the primary purpose of the research is to understand the causes, development and effects of disease or to improve preventative, diagnostic or therapeutic interventions, must register their trials prior to submission in a suitable publicly available registry. In addition to accepting registration in any of the five existing registries (/faq.html), the ICMJE will accept registration of clinical trials in any of the primary registers that participate in the WHO International Clinical Trials Registry Platform including the ISRCTN register administered by Current Controlled Trials, part of BioMed Central Group.The trial registration number should be included as the last line of the manuscript abstract. Data and materials releaseSubmission of a manuscript to Journal of Translational Medicine implies that readily reproducible materials described in the manuscript, including all relevant raw data, will be freely available to any scientist wishing to use them for non-commercial purposes. Nucleic acid sequences, protein sequences, and atomic coordinates should be deposited in an appropriate database in time for the accession number to be included in the published article. In computational studies where the sequence information is unacceptable for inclusion in databases because of lack of experimental validation, the sequences must be published as an additional file with the article.Any 'in press' articles cited within the references and necessary for the reviewers' assessment of the manuscript should be made available if requested by the editorial office.Nucleotide sequencesNucleotide sequences can be deposited with the DNA Data Bank of Japan(DDBJ), European Molecular Biology Laboratory (EMBL/EBI) Nucleotide Sequence Database, or GenBank (National Center for Biotechnology Information).Protein sequencesProtein sequences can be deposited with SwissProt or the Protein Information Resource (PIR).The accession numbers of any nucleic acid sequences, protein sequences or atomic coordinates cited in the manuscript should be provided, in square brackets with the corresponding database name; for example, [EMBL:AB026295, EMBL:AC137000, DDBJ:AE000812, GenBank:U49845, PDB:1BFM, Swiss-Prot:Q96KQ7, PIR:S66116].The databases for which we can provide direct links are: EMBL Nucleotide Sequence Database (EMBL), DNA Data Bank of Japan (DDBJ), GenBank at the NCBI (GenBank), Protein Data Bank (PDB), Protein Information Resource (PIR) and the Swiss-Prot Protein Database (Swiss-Prot).Mass spectrometryCompeting interestsJournal of Translational Medicine requires authors to declare any competing financial or other interest in relation to their work. All competing interests that are declared will be listed at the end of published articles. Where an author gives no competing interests, the listing will read 'The author(s) declare that they have no competing interests'.Plagiarism detectionJournal of Translational Medicine's publisher, BioMed Central, is a member of the CrossCheck plagiarism detection initiative. In cases of suspected plagiarism CrossCheck is available to the editors of Journal of Translational Medicine to detect instances of overlapping and similar text in submitted manuscripts. CrossCheck is a multi-publisher initiative allowing screening of published and submitted content for originality.Citing articles in Journal of Translational MedicineArticles in Journal of Translational Medicine should be cited in the same way as articles in a traditional journal. Because articles are not printed, they do not have page numbers; instead, they are given a unique article number.Article citations follow this format:Authors: Title. J Transl Med [year], [volume number]:[article number].e.g. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome Proliferator-Activated Receptor delta from Peroxisome Proliferator-Activated Receptor gamma in the Ob/Ob mouse. J Transl Med 2009, 1:115.refers to article 115 from Volume 1 of the journal.Why publish your article in Journal of Translational Medicine?High visibilityJournal of Translational Medicine's open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience. Articles that have been especially highly accessed are highlighted with a 'Highly accessed' graphic, which appears on the journal's contents pages and search results.Speed of publicationJournal of Translational Medicine offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles are published with their final citation immediately upon acceptance in a provisional PDF form. The article will subsequently be published in both fully browsable web form, and as a formatted PDF; the article will then be available through Journal of Translational Medicine, BioMed Central and PubMed Central and will also be included in PubMed.FlexibilityOnline publication in Journal of Translational Medicine gives authors the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves, and to create all relevant links (for example, to PubMed, to sequence and other databases, and to other papers).Promotion and press coverageArticles published in Journal of Translational Medicine are included in article alerts and regular email updates. Some may be included in abstract books mailed to academics and are highlighted on Journal of Translational Medicine's pages and on the BioMed Central homepage.In addition, articles published in Journal of Translational Medicine may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of accesses for articles published in Journal of Translational Medicine. A list of articles recently press-released by journals published by BioMed Central is available here.CopyrightAuthors of articles published in Journal of Translational Medicine retain the copyright of their articles and are free to reproduce and disseminate their work (for further details, see the BioMed Central copyright and license agreement).For further information about the advantages of publishing in a journal from BioMed Central, please click here..。
医学核心期刊目录2023
医学核心期刊目录2023引言医学核心期刊是医学领域的重要资源，为医学研究人员、临床医生和其他从事医学相关工作的人提供了宝贵的信息。
在选择合适的期刊进行投稿或查阅最新的研究成果时，了解医学核心期刊的目录是至关重要的。
本文将介绍医学核心期刊的目录2023年最新版，以帮助读者快速了解并选择合适的期刊。
什么是医学核心期刊？医学核心期刊是指被国际权威医学数据库或索引收录的具有较高学术影响力，发表质量较高的医学研究论文的期刊。
这些期刊在医学领域具有较高的声誉和影响力，因此被广泛认可和引用。
医学核心期刊的收录权威性由医学界的权威机构或学会评定，如美国国家医学图书馆（NLM）的医学数据库PubMed。
医学核心期刊目录2023以下是医学核心期刊目录2023年的一些重要期刊，按照不同的医学领域进行分类：1. 临床医学•The New England Journal of Medicine•The Lancet•JAMA - The Journal of the American Medical Association•BMJ - British Medical Journal•Annals of Internal Medicine•Clinical Infectious Diseases2. 生物医学研究与实验•Nature Medicine•Cell•Science Translational Medicine•Journal of Experimental Medicine•Molecular Cell•Stem Cell Reports3. 公共卫生与流行病学•The Lancet Public Health•American Journal of Public Health•International Journal of Epidemiology•Annual Review of Public Health•The New England Journal of Medicine - Public Health4. 肿瘤学•Cancer Cell•Journal of Clinical Oncology•Nature Reviews Cancer•Cancer Research•Clinical Cancer Research•Cancer Discovery5. 心脑血管疾病•Circulation•European Heart Journal•JACC: Journal of the American College of Cardiology •Stroke•Heart•Journal of the American Heart Association6. 内分泌学与代谢•Diabetes•Diabetes Care•Journal of Clinical Endocrinology and Metabolism •Nature Reviews Endocrinology•The Lancet Diabetes & Endocrinology7. 神经科学•Nature Neuroscience•Neuron•Trends in Cognitive Sciences•CNS Drugs•Molecular Psychiatry•Neurology8. 儿科学•Pediatrics•Journal of Pediatrics•Archives of Disease in Childhood•The Lancet Child & Adolescent Health•Journal of Child Psychology and Psychiatry •Pediatric Research9. 传染病学•The Lancet Infectious Diseases•Clinical Infectious Diseases•Emerging Infectious Diseases•Nature Reviews Microbiology•Journal of Infectious Diseases•BMC Infectious Diseases10. 免疫学•Nature Immunology•Immunity•Annual Review of Immunology•Frontiers in Immunology•Journal of Allergy and Clinical Immunology•Trends in Immunology结论医学核心期刊目录是医学研究人员、临床医生和其他从事医学相关工作的人的重要参考资源。
临床医学中的转化医学研究
临床医学中的转化医学研究转化医学（Translational Medicine）是近年来兴起的一门学科，旨在将基础科研的成果转化为临床实践中的应用，从而推动医学进步，提高临床治疗效果和患者生存率。
在临床医学中，转化医学研究发挥着重要的作用，为疾病的早期诊断、个体化治疗和新药开发提供了理论和指导。
一、转化医学的概念与意义转化医学指的是将基础医学研究和临床医学紧密结合起来，将实验室的研究成果应用于人类临床实践中。
通过研究人类疾病的分子机制、生物学特性以及个体差异，转化医学可以更准确地诊断和治疗疾病，帮助患者获得更好的临床效果。
同时，转化医学也为研发新药和新治疗方法提供了科学依据，推动了医学的进步与发展。
转化医学的意义在于缩短基础研究到临床应用的时间，将科学研究成果迅速转化为临床实践中的应用。
这种转化过程有助于解决临床医学实践中的问题，并为患者提供更加精确和个体化的治疗方案，提高治疗效果和生活质量。
二、转化医学研究的内容与方法转化医学研究的内容十分广泛，涉及从患者样本的收集、基因组学、蛋白质组学等分子生物学研究，到动物模型的构建和临床试验的设计等多个层面。
这些研究内容贯穿整个转化医学过程，旨在加深对疾病机制的理解、发现新的治疗靶点，并验证其在临床治疗中的可行性。
转化医学研究的方法多样，常见的包括基因测序技术、分子定量分析、细胞培养、动物模型构建以及临床试验设计等。
这些方法的综合应用可以帮助研究者从多个层面多个维度来探索疾病的机制和治疗方法。
三、转化医学的应用案例1. 个体化治疗转化医学通过研究个体的基因组和蛋白质组等分子特征，为患者提供个体化的治疗方案。
例如，在肿瘤治疗中，通过对肿瘤组织的基因测序和蛋白质定量分析，可以判断患者对不同药物的敏感性，并提供相应的个体化治疗方案，提高治疗效果。
2. 新药开发转化医学为新药研发提供了理论和指导。
通过研究疾病的分子机制和信号通路，转化医学可以发现新的治疗靶点，并验证其在临床治疗中的可行性。
“科学禁食法”真能降低重大疾病风险？
“科学禁食法”真能降低重大疾病风险？每隔几个月采用一种为期5天的特殊饮食，在其他时候不改变日常饮食的情况下减轻体重并降低重大疾病风险，这个主意怎么样？由美国南加州大学（USC）Leonard Davis老年医学系主导的这项研究，在第二阶段的实验中，有71名成年人进行了三轮这种低热量“禁食模拟饮食法”(fasting-mimicking diet,FMD)，并且取得了这样的效果。
该研究表明，这种“科学禁食法”具有诸多益处。
该饮食方式能够降低心血管疾病风险因素，包括血压、炎症迹象（基于c-反应蛋白水平）、空腹血糖，并降低IGF-1的水平，IGF-1是一种影响代谢的激素。
该饮食方式还能减小腰围、减轻体重、全身体脂和躯干部体脂，但是不会影响肌肉质量。
听着好棒！根据2月15日发表在《科学转化医学（Science Translational Medicine）》上的研究结果，实际上，这种饮食方式还能降低受测者的癌症、糖尿病、心脏病及其他与年龄相关疾病的风险。
USC长寿研究所的负责人Valter Longo说：“这项研究表明，人们可以通过周期性模拟禁食的饮食方式获得很多的健康益处，这种饮食方式的设计目的是应对衰老过程。
过去的研究证实这种方式能够使小鼠获得很多健康益处。
但这次是有足够人数参与的首次随机临床试验，证明了这种饮食方式对人类是可行的、有效的和安全的。
为了获得FDA的认可，我们还需要更大规模的实验确认这种方式对疾病预防和治疗的效果。
”有100人参与了这项试验，从2013年4月至2015年7月。
他们的年龄在20至70岁之间，身体都是健康的，他们被分为两组进行随机试验。
对照组的受测者被要求持续三个月采用正常的饮食方式。
而试验组的受测者们在这三个月内要采用模拟禁食的饮食方式。
这种特殊的饮食方式要求受测者们每个月中在禁食的五天内吃L-Nutra公司提供的食品。
这种饮食方式的设计目的是模拟只喝水的禁食结果，允许受测者每天摄入750至1100卡路里的热量。
免疫磁珠联合拉曼探针实现埃博拉病毒的POCT检测
近日，科学转化医学（Science Translational Medicine，影响因子=16.710）发表题为“A point-of-care diagnostic for differentiating Ebola from endemic febrile diseases”的研究文章，报道了一种磁珠捕获联合拉曼探针的SERS（表面增强拉曼散射）多元检测POCT技术，能够从流行发热性疾病中有效诊断出埃博拉疾病。
出血热疫情爆发，例如埃博拉病毒，由于缺乏低成本和易操作的检测方法以及初始临床症状类似其他疾病（如拉沙热），导致其难于检测和控制。
目前的分子诊断方法如PCR检测，需要专业的人员与实验设施，因此妨碍了疫情现场的及时检测。
尽管侧向流免疫层仪等快速检测方法已经被广泛开展，但是不能很好地区分具有类似症状的多种疾病。
早期检测与控制埃博拉病毒爆发需要简单和易于操作的方法，以便于从其它更常见的拉沙热疾病中区分出埃博拉病毒感染。
在这个研究中，研究者们发展了一种简单的免疫检测方法，他们利用磁珠联合拉曼探针来同时地检测同一份血液样本中埃博拉病毒、拉沙热病毒和疟疾的不同抗原，并且30分钟内即可以完成单个或批处理样品的检测（检测原理见图1）。
利用2014年西非埃博拉疫情爆发采集的190份临床样本，163份疟疾阳性对照和233份阴性对照，实验结果展示了埃博拉检测具有90.0%敏感性和97.9%特异性，而疟疾检测具有100.0%敏感性和99.6%特异性。
这些结果以及相应的活病毒和对非人灵长类动物埃博拉病毒、拉沙热病毒和疟疾的检测，指出SERS技术作为重要工具将对资源贫乏环境下疫情检测和临床分类具有重大潜力。
图1. 采用磁珠联合拉曼探针检测埃博拉病毒、拉沙热病毒、疟疾的原理示意图。
A. 拉曼探针技术原理：拉曼探针采用60nm金纳米颗粒作为信号增强介质，表面吸附不同的拉曼信号分子做为检测不同病毒的指纹；外壳为20-30nm的氧化硅包覆层，就可以阻止拉曼分子泄露，又可以防止检测体系中干扰物的影响；外表面修饰针对不同病毒抗原的特异性抗体。
clinical and translational medicine参考文献
clinical and translational medicine参考文献Clinical and Translational MedicineIntroduction:Clinical and Translational Medicine (CTM) is an interdisciplinary field that focuses on translating scientific discoveries into medical practices. It aims to bridge the gap between basic research and clinical application, ultimately improving patient outcomes and public health. This article will explore the importance of CTM, discuss its challenges, and provide references to support the discussion.Importance of Clinical and Translational Medicine:1. Translating Scientific Discoveries: CTM plays a crucial role in translating laboratory findings into clinical studies. It ensures that promising discoveries are further investigated, validated, and eventually integrated into patient care.2. Personalized Medicine: Advancements in genomics, proteomics, and other technologies have led to personalized medicine. CTM facilitates the translation of these techniques into clinical practice, allowing for tailored treatments based on a patient's genetic profile.3. Drug Development: CTM bridges the gap between preclinical drug development and clinical trials. It enables researchers to understand the safety and efficacy of potential drugs in human subjects, leading to the development of novel therapies.4. Improving Diagnosis and Treatment: CTM encourages the implementation of innovative diagnostic tools and treatment strategies. It enables the evaluation of new diagnostic biomarkers, imaging techniques, and therapeutic interventions, ultimately improving patient care.Challenges in Clinical and Translational Medicine:1. Collaborative Research: CTM relies on collaboration between basic scientists, clinical researchers, healthcare providers, and industry partners. Coordinating these interdisciplinary teams and fostering effective communication can be challenging.2. Funding: Translational research requires substantial funding, often beyond what is available through traditional academic grants. Securing financial support for clinical trials, infrastructure, and technology is a persistent challenge.3. Regulatory Hurdles: Clinical research is subject to rigorous regulatory oversight to ensure patient safety. Complying with ethical guidelines, obtaining appropriate approvals, and navigating complex regulatory pathways can be time-consuming and resource-intensive.4. Data Integration: The integration of data from different sources, including electronic health records, genetic databases, and biomedical literature, poses challengesin standardization, harmonization, and analysis. Developing tools for data integration and analysis is essential for efficient translation.References:1. Collins FS, et al. (2009). A strategy for personalized medicine. Science, 20:363-4.2. Califf RM, et al. (2012). Transforming Evidence Generation to Support Health and Health Care Decisions. N Engl J Med, 367(8): 746-749.3. Zerhouni EA. (2005). Translational and clinical science-time for a new vision. N Engl J Med, 353(15):1621-3.4. Ioannidis JPA. (2016). The Translational Imperative: Next Steps. JAMA, 315(3): 255-256.Conclusion:Clinical and Translational Medicine is a vital field that bridges the gap between scientific discoveries and their clinical applications. Through collaboration, innovative research methods, and effective translation, CTM has the potential to significantly impactpatient care and public health. However, challenges such as funding, regulation, and data integration need to be addressed to fully harness the benefits of CTM. By referring to the provided references, researchers and healthcare professionals can further explore the vast potential of CTM in improving medical practice and patient outcomes.。
- 1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。
science translational medicine介绍
【原创实用版】
目录
1.Science Translational Medicine 期刊简介
2.Science Translational Medicine 的创刊历史和使命
3.Science Translational Medicine 的主要内容和特点
4.Science Translational Medicine 的影响力和地位
5.Science Translational Medicine 的投稿要求和审稿流程
正文
Science Translational Medicine（STM）是一本由美国科学促进会（AAAS）出版的医学研究期刊，旨在促进基础研究与临床医学之间的交流和转化。
该期刊创刊于 2009 年，其使命是通过发表具有转化潜力的研究成果，推动医学科学的发展，以改善人类健康。
Science Translational Medicine 的创刊历史可以追溯到 2009 年，当时正值全球医学研究领域对转化医学的关注度不断提高。
作为一本具有高度影响力的科学期刊，STM 自创刊以来，一直致力于为全球医学研究者提供一个分享和交流的平台。
STM 主要内容包括生物医学研究的各个领域，如分子生物学、细胞生物学、生理学、病理学、药理学等。
该期刊的特点在于强调研究的转化潜力，关注基础研究与临床医学之间的联系。
同时，STM 也关注医学伦理、政策和监管等方面的议题，以期为医学科学的发展提供全面的支持。
Science Translational Medicine 在医学研究领域具有很高的影响力和地位。
该期刊被多家国际权威学术评价机构收录，并拥有较高的影响因子。
在全球范围内，STM 吸引了大量优秀的医学研究者投稿，竞争激烈。
对于有意向向 Science Translational Medicine 投稿的研究者，需
要遵循期刊的投稿要求和审稿流程。
投稿要求包括：论文必须是原创研究成果，数据真实可靠，且具有转化潜力。
论文格式需符合期刊规定，同时需提交完整的作者信息和利益冲突声明。
在投稿过程中，作者需要通过期刊官网提交论文，并提供详细的作者信息和论文摘要。
之后，论文将进入审稿流程，由期刊聘请的国际专家进行同行评议。
根据审稿意见，作者需对论文进行修改，并提交最终稿。
最后，期刊将根据评审结果决定是否接受论文发表。
总之，Science Translational Medicine 是一本具有很高影响力的医学研究期刊，旨在推动基础研究与临床医学之间的转化。